Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Darunavir (Prezista®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0311. 2011 Authors' conclusions Darunavir (Prezista®) co-administered with low dose ritonavir, in combination with other antiretroviral medicinal products, is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral treatment (ART)-experienced children and adolescents from the age of 6 years and at least 20 kg body weight.
Darunavir (Prezista®) should be prescribed in accordance with Paediatric European Network for Treatment of Aids (PENTA) guidelines.
Darunavir (Prezista®) is not suitable for shared care within NHS Wales for the above indication. Indexing Status Subject indexing assigned by CRD MeSH HIV Infectionss; HIV Protease Inhibitors; Sulfonamides Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000363 Date abstract record published 08/08/2012 |
